Glycosaminoglycan treatment in glomerulonephritis? An interesting option to investigate.
暂无分享,去创建一个
[1] L. P. Van den Heuvel,et al. Heparan sulfate on activated glomerular endothelial cells and exogenous heparinoids influence the rolling and adhesion of leucocytes. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] J. Clorius,et al. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system. , 2006, Clinical journal of the American Society of Nephrology : CJASN.
[3] C. Takiya,et al. Effects of low molecular weight heparin in obstructed kidneys: decrease of collagen, fibronectin and TGF-beta, and increase of chondroitin/dermatan sulfate proteoglycans and macrophage infiltration. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[4] M. Cooper,et al. Heparanase inhibition reduces proteinuria in a model of accelerated anti‐glomerular basement membrane antibody disease , 2005, Nephrology.
[5] B. Yard,et al. Modulation of angiotensin II-mediated signalling by heparan sulphate glycosaminoglycans. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[6] G. Gambaro,et al. Heparin reduces glomerular infiltration and TGF-beta protein expression by macrophages in puromycin glomerulosclerosis. , 2003, Journal of nephrology.
[7] A. Cupisti,et al. Effect of heparan sulphate on kidney tissue expression of TGF-beta, rhoA, laminin and fibronectin in subtotally nephrectomized rats. , 2002, Journal of nephrology.
[8] A. Varki,et al. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. , 2002, The Journal of clinical investigation.
[9] W. Grzeszczak,et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. , 2002, Journal of the American Society of Nephrology : JASN.
[10] G. Gambaro,et al. Low-molecular-weight heparin prevents high glucose- and phorbol ester-induced TGF-beta 1 gene activation. , 2001, Kidney international.
[11] V. Laux,et al. Treatment of chronic renal allograft rejection in rats with a low-molecular-weight heparin (reviparin). , 2001, Transplantation.
[12] U. Sauer,et al. Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. , 2000, Journal of the American Society of Nephrology : JASN.
[13] J. Floege,et al. Differential activation of mitogen-activated protein kinases in experimental mesangioproliferative glomerulonephritis. , 2000, Journal of the American Society of Nephrology : JASN.
[14] G. Gambaro,et al. Glycosaminoglycans: use in treatment of diabetic nephropathy. , 2000, Journal of the American Society of Nephrology : JASN.
[15] G. Gambaro,et al. Mesangial Cell Proliferation in Long-Term Streptozotocin-Induced Diabetes mellitus in the Rat and the Renoprotective Activity of Heparin , 1999, American Journal of Nephrology.
[16] A. Cupisti,et al. Effects of Oral Administration of Heparan Sulphate in the Rat Remnant Kidney Model , 1999, Nephron.
[17] G. Gambaro,et al. Glycosaminoglycan therapy for long-term diabetic complications? , 1998, Diabetologia.
[18] A. Varki,et al. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. , 1998, The Journal of clinical investigation.
[19] K. Koch,et al. Treatment of experimental mesangioproliferative glomerulonephritis with non-anticoagulant heparin: therapeutic efficacy and safety. , 1997, Laboratory investigation; a journal of technical methods and pathology.
[20] B. Walgreen,et al. Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice. , 1996, Kidney international.
[21] G. Gambaro,et al. Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[22] U. Sauer,et al. Increased glomerular alpha 1 (IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[23] H. Yokoyama,et al. Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats , 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[24] G. Gambaro,et al. Heparin modulates proliferation and proteoglycan biosynthesis in murine mesangial cells: molecular clues for its activity in nephropathy. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[25] Y. Oshima,et al. Protective effect of heparin on renal glomerular anionic sites of streptozotocin-injected rats. , 1994, Diabetes research and clinical practice.
[26] G. Gambaro,et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. , 1994, Kidney international.
[27] H. Makino,et al. Beneficial effect of low molecular weight heparin ("fragmin") on proteinuria of proliferative glomerulonephritis. , 1994, Clinical nephrology.
[28] M. Baggiolini,et al. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[29] W. Couser,et al. Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. , 1993, Kidney international.
[30] C. Alpers,et al. Rat glomerular mesangial cells synthesize basic fibroblast growth factor. Release, upregulated synthesis, and mitogenicity in mesangial proliferative glomerulonephritis. , 1992, The Journal of clinical investigation.
[31] G. Gambaro,et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. , 1992, Kidney international.
[32] C. Alpers,et al. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. , 1992, Kidney international.
[33] M. Karnovsky,et al. Antiproliferative effects of novel, nonanticoagulant heparin derivatives on vascular smooth muscle cells in vitro and in vivo. , 1991, The American journal of pathology.
[34] A. Gown,et al. Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[35] G. Striker,et al. Mesangial cell turnover: effect of heparin and peptide growth factors. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[36] B. Caleb,et al. Heparin selectively inhibits a protein kinase C-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells [published erratum appears in J Cell Biol 1990 Mar;110(3):863] , 1989, The Journal of cell biology.
[37] R A Laskey,et al. S phase of the cell cycle. , 1989, Science.
[38] H. Nader,et al. Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells , 1989, Journal of cellular physiology.
[39] A. Gallus,et al. Focal glomerulosclerosis treated with heparin. , 1989, Archives of disease in childhood.
[40] G. Sonenshein,et al. Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. , 1989, The Journal of biological chemistry.
[41] S. Klahr,et al. Effect of heparin on the glomerular structure and function of remnant nephrons. , 1988, Kidney international.
[42] A. Coffey,et al. Heparin inhibits mesangial cell proliferation in habu-venom-induced glomerular injury. , 1985, The American journal of pathology.
[43] S. Klahr,et al. Inhibition by anticoagulant drugs of the progressive hypertension and uremia associated with renal infarction in rats. , 1982, Thrombosis research.
[44] G. Gambaro,et al. The Role of Glycosaminoglycans and Sulodexide in the Treatment of Diabetic Nephropathy , 2006, Treatments in endocrinology.
[45] N. Yoshikawa,et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. , 1999, Journal of the American Society of Nephrology : JASN.
[46] P. Furness,et al. Heparin inhibits the binding of immune complexes to cultured rat mesangial cells. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[47] S. Klahr,et al. N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. , 1988, The Journal of clinical investigation.
[48] M. Karnovsky,et al. Nonanticoagulant protective effect of heparin in chronic aminonucleoside nephrosis. , 1986, Renal physiology.
[49] D. Shires,et al. The effect of long term high dose heparin treatment on the course of chronic proliferative glomerulonephritis. , 1971, Nephron.